Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Patients with advanced bladder cancer benefit from anti-PD-L1 immunotherapy

2016 ASCO Annual Meeting

Published: 5 Jun 2016

Views: 2125

Rating:

Save

Dr Arjun Balar - NYU Langone Medical Center, New York, USA

Dr Balar presents at ASCO 2016, results from a non-randomised phase II trial which showed that anti-PD-L1 immunotherapy atezolizumab is effective in patients with previously untreated advanced bladder cancer and not eligible for the standard treatment with cisplatin.

Read the news story for more.

Related Videos

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic urothelial cancer across all exposure quartiles

Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic urothelial cancer across all exposure quartiles ( Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA )

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive urothelial bladder cancer

Dr Antonio Cigliola - IRCCS San Raffaele Hospital, Milan, Italy

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive urothelial bladder cancer ( Dr Antonio Cigliola - IRCCS San Raffaele Hospital, Milan, Italy )

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

Pembrolizumab a promising option for MIUC patients after radical surgery

Dr Andrea Apolo - National Cancer Institute, Bethesda, USA

Pembrolizumab a promising option for MIUC patients after radical surgery ( Dr Andrea Apolo - National Cancer Institute, Bethesda, USA )

Remote genetic testing has the potential to increase the uptake of testing in large integrated healthcare systems

Dr Bruce Montgomery - University of Washington, Seattle, USA

Remote genetic testing has the potential to increase the uptake of testing in large integrated healthcare systems ( Dr Bruce Montgomery - University of Washington, Seattle, USA )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer